Moderna Exceeds Q3 Estimates and Raises 2026 Revenue Growth Guidance
Moderna (MRNA) reported third-quarter results that significantly outperformed Wall Street expectations, posting revenue of $1.31 billion against an expected $885.1 million. The company transitioned from a net loss in the previous year to a net income of $162 million for the quarter, driven by strong international Covid vaccine sales and long-term government partnerships. Following these results, CEO Stéphane Bancel raised the 2026 revenue growth outlook to a range of 15% to 25%, up from the previous guidance of 10%. This optimism is fueled by the momentum of next-generation mRNA Covid vaccines and upcoming launches for stand-alone flu shots. Despite recent stock volatility following leaked clinical data, management remains confident in their diversified product pipeline, including experimental cancer vaccine developments.
Tickers: $MRNA
Topics: biotechnology earnings report guidance hike revenue growth vaccines
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)